

## 14<sup>th</sup> MMV Stakeholders' Meeting

# Critical challenges to malaria elimination in S.E. Asia

11- 12 October 2017, Sheraton Bali Kuta Resort, Bali

**WEDNESDAY, 11 October @ 12:00 – 17.00**

Time	Topic	Speaker
<b>12.00-13.00</b>	<b>Buffet lunch</b>	<b>Restaurant Feast</b>
13.00-13.20	Announcements Introduction to MMV stakeholders' meeting	Dr David Reddy, CEO, MMV
13.20-13.35	Inauguration and opening remarks	Dr Pretty Multihartina, Director of Centre of Research and Development for Biomedical and Basic Technology of Health, National Institute of Health Research and Development, Ministry of Health, Indonesia
13.35-13.55	The importance of partnerships in global health	Ms Joy Phumaphi, Executive Secretary, ALMA, Botswana
13.55-14.00	Screening of MMV film	Dr David Reddy
<b>SESSION 1: Malaria strategy post-2015 – the quest for elimination</b>		
<b>14.00-15.30 (90 mins)</b>	<b>Chair: Mr Alan Court, UN Special Envoy's Office</b>	
15 mins	<ul style="list-style-type: none"> <li>15 years of progress in the fight against malaria</li> </ul>	H.E. Dr Kesetebirhan Admasu, CEO, RBM
15 mins	<ul style="list-style-type: none"> <li>WHO's Global Technical Strategy 2016-2030</li> </ul>	Dr Peter Olumese, WHO GMP
45 mins	<ul style="list-style-type: none"> <li>Key challenges to implementing the global strategy (<i>15 mins each</i>)               <ul style="list-style-type: none"> <li>Treatment of multi-drug resistant malaria</li> <li>Regional challenges: So near and yet so far</li> <li>Resolving financial constraints</li> </ul> </li> </ul>	Dr Rob van der Pluijm, Mahidol Dr Ben Rolfe, CEO, APLMA Mr Alan Court, UNSEO
15 mins	Discussion	Chair
<b>15.30-16.00</b>	<b>Coffee break</b>	



<b>16.00-17.00</b>	<b>MMV: Prioritizing elimination</b>	
5 mins	<ul style="list-style-type: none"> <li>Launch of MMV's 5<sup>th</sup> Business Plan</li> </ul>	Alan Court, UNSEO and MMV Board member
10 mins	<ul style="list-style-type: none"> <li>Screening of film on the Business Plan</li> </ul>	Dr David Reddy, CEO MMV
10 mins	Supporting the global agenda - MMV and the next 5 years	Mr George Jagoe, EVP APM
10 mins	The journey to impact	Dr Tim Wells, CSO, MMV
10 mins	Building the tools to drive elimination and save lives	
15 mins	Discussion	Chair

<b>19.00</b>	<b>Departure for Opening Dinner at Taman Bhagawan</b>	
10 mins	Welcome speech	Mr Alan Court, UNSEO and MMV Board member
10 mins	<b>Keynote speech:</b> "The best is yet to come..."	Prof Marcel Tanner, President Swiss Academy of Sciences, Director Emeritus Swiss TPH
15 mins	Project of the year 2016 award	Introduction: Dr David Reddy <i>P. vivax</i> assays team: <ul style="list-style-type: none"> <li>Dr Elizabeth Winzeler</li> <li>Dr Jetsumon Prachumsri</li> </ul>

**THURSDAY, 12 October @ 08.30-17.30h**

Time	Topic	Speaker
	<b>Breakfast</b>	<b>Restaurant Feast</b>
<b>SESSION 2: Achieving impact by improving access to today's medicines</b>		
<b>09.00-10.30 (90 mins)</b>	<b>Chair: Mr George Jagoe, EVP, Access and Product Management, MMV</b>	
15 mins	<ul style="list-style-type: none"> <li>Protecting pregnant women from malaria: exploring new options</li> </ul>	Dr Rini Poespoprodjo, Timika Research Facility, Indonesia; and Dr Rukhsana Ahmed, LSTM
20 mins	<ul style="list-style-type: none"> <li>Pyronaridine artesunate: Creating new access and expanding the evidence base for the most recent EMA-approved ACT</li> </ul>	Mr Won June Chang, Shin Poong Pharmaceutical Co Ltd, Korea
20 mins	<ul style="list-style-type: none"> <li>Injectable artesunate: Increasing patient survival through WHO's recommended treatment for severe malaria</li> </ul>	Ms Lily Su, Guilin Pharmaceutical Co Ltd, China
20 mins	<ul style="list-style-type: none"> <li>Expanding access channels at the community level: Pioneering CCMP work in Odisha, India</li> </ul>	Dr Madan M Pradhan, NVBDCP, Odisha, India
15 mins	Discussion	Chair
<b>10.30-11.00</b>	<b>Coffee break</b>	



<b>SESSION 3: New opportunities for expanding access to improved treatment for relapsing malaria</b>		
<b>11.00-12.30 (90 mins)</b>	<b>Chair: Dr Ben Rolfe, CEO, APLMA</b>	
15 mins	<ul style="list-style-type: none"> <li>Genesis, evidence base and strategy of the 2015 WHO <i>Plasmodium vivax</i> Technical Brief</li> </ul>	Prof Kevin Baird, Eijkman-Oxford Clinical Research Unit (EOCRU), Indonesia
15 mins	<ul style="list-style-type: none"> <li><i>P. vivax</i> malaria – the burden and consequences of not fully treating patients with radical cure</li> </ul>	Prof Ric Price; Menzies School of Health Research, Australia
60 mins	<p><b>REGIONAL PERSPECTIVES</b></p> <p>The challenges of the programmatic management of radical cure for <i>P. vivax</i> malaria (15 mins each).</p> <ul style="list-style-type: none"> <li>PNG’s expanding malaria programme</li> <li>Indonesia’s progress in planning for the control and elimination of <i>P. vivax</i></li> <li>Brazil’s malaria elimination programme</li> </ul>	<p>Dr Leo Makita, PNG</p> <p>Dr Iriani Samad, NMCP, Indonesia</p> <p>Dr Marcus Lacerda, Brazil</p>
<b>12.30-14.00</b>	<b>Lunch</b>	
<b>SESSION 4: Next generation tools for blood-stage infection</b>		
<b>14.00-15.10 (70 mins)</b>	<b>Chair: Dr Janice Culpepper, Senior Program Officer, Bill &amp; Melinda Gates Foundation</b>	
25 mins	<ul style="list-style-type: none"> <li>Translational and product development at MMV <ul style="list-style-type: none"> <li>Artefenomel/Ferroquine (10 mins)</li> <li>KAF156 (10 mins)</li> </ul> </li> </ul>	Dr Tim Wells, MMV
20 mins		Dr David Hughes, Novartis
5 mins	<ul style="list-style-type: none"> <li>Celgene’s malaria programme</li> </ul>	Dr Joe Camardo, Celgene
20 mins	Discussion	Chair
<b>15.10-15.30</b>	<b>Coffee break</b>	
<b>SESSION 5: Next generation tools for relapsing malaria</b>		
<b>15.30-17.15 (105 mins)</b>	<b>Chair: Professor Kevin Baird, Eijkman-Oxford Clinical Research Unit (EOCRU)</b>	
30 mins	<ul style="list-style-type: none"> <li>Developing a drug for relapsing malaria: The TQ programme</li> </ul>	Dr Marcus Lacerda, Brazil
20 mins	<ul style="list-style-type: none"> <li>Relapse behaviours in chemotherapeutic assessments</li> </ul>	Prof Kevin Baird, (EOCRU)
15 mins	<ul style="list-style-type: none"> <li>MMV’s longer-term anti-relapse strategy: The discovery of new molecules</li> </ul>	Dr Brice Campo, MMV
30 mins	New assays to screen compounds against liver stages of malaria (15 mins each)	<ul style="list-style-type: none"> <li>Dr Elizabeth Winzeler, UCSD</li> <li>Dr Jetsumon Prachumsri, Mahidol</li> </ul>
10 mins	Discussion	Chair
<b>17.15-17.30</b>	<b>Wrap-up</b>	
	Concluding remarks	Dr David Reddy
<b>19.00</b>	<b>Informal dinner at North Courtyard, Sheraton</b>	

